JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

Home・Elenco Azioni・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Chiusa

SettoreSettore sanitario

11.09 -3.65

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.09

Massimo

11.55

Metriche Chiave
By Trading Economics
Entrata	11M -20M
Vendite	5.9M 40M
Margine di Profitto	-49.569
Dipendenti	184
EBITDA	16M -19M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+99.73% upside

Dividendi
By Dow Jones
Utili prossimi	24 feb 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	486M 1.2B
Apertura precedente	14.74
Chiusura precedente	11.09

Notizie sul Sentiment di mercato

By Acuity

50%

147 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

6.26 / 7.47 Supporto e resistenza

Day One Biopharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 feb 2026, 23:11 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Utili

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisizioni, Fusioni, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Discorsi di Mercato

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Utili

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Utili

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Utili

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Utili

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Utili

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Utili

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Utili

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Discorsi di Mercato

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Utili

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Utili

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Utili

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Confronto tra pari

Modifica del prezzo

Day One Biopharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

99.73% in crescita

Previsioni per 12 mesi

Media 22.29 USD 99.73%

Alto 29 USD

Basso 16 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

6.26 / 7.47Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

147 / 352 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.